{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:56Z","timestamp":1786997876802,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006474","name":"Columbia University","doi-asserted-by":"publisher","award":["10\/07\/2024"],"award-info":[{"award-number":["10\/07\/2024"]}],"id":[{"id":"10.13039\/100006474","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.urolonc.2025.02.004","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:29:44Z","timestamp":1739978984000},"page":"440.e11-440.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of age on BCG treatment response"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3805-971X","authenticated-orcid":false,"given":"J. Patrick","family":"Tavelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainjade","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Gorroochurn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7062-5001","authenticated-orcid":false,"given":"Christopher B.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.02.004_bib0001","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0002","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0003","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2022.900028","article-title":"Immune senescence, immunosenescence and aging","volume":"3","author":"Lee","year":"2022","journal-title":"Front Aging."},{"key":"10.1016\/j.urolonc.2025.02.004_bib0006","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminoncol.2018.08.006","article-title":"Aging,\u202fimmune senescence,\u202fand immunotherapy:\u202fa comprehensive review","volume":"45","author":"Elias","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0007","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Montorsi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0009","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance Bacillus Calmette-Guerin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC Genito-urinary group study 30911","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0010","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0011","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bju.16127","article-title":"Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin","volume":"133","author":"Contieri","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0012","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0013","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1464-410X.2009.09076.x","article-title":"The effect of age and gender on bladder cancer: a critical review of the literature","volume":"105","author":"Shariat","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0014","series-title":"SEER*Explorer: an interactive website for SEER cancer statistics [Internet]. In: surveillance research program NCI, editor","year":"2024"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0016","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.urology.2008.01.062","article-title":"Relationship between patient age and superficial transitional cell carcinoma characteristics","volume":"71","author":"Shi","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0017","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1464-410X.2008.08033.x","article-title":"The prognostic significance of advanced age in patients with bladder cancer treated with radical cystectomy","volume":"103","author":"Resorlu","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0018","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/1097-0142(19890701)64:1<178::AID-CNCR2820640130>3.0.CO;2-B","article-title":"Bladder carcinoma in patients age 40 years or younger","volume":"64","author":"Wan","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0019","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0022-5347(17)44046-8","article-title":"The natural history of patients less than 40 years old with bladder tumors","volume":"137","author":"Kurz","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0022-5347(17)57090-1","article-title":"Carcinoma of the bladder in patients less than 40 years old","volume":"120","author":"Johnson","year":"1978","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0021","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000000593","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort","volume":"203","author":"Ritch","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0022","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0023","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0024","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jjco\/hyq241","article-title":"Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy?","volume":"41","author":"Yuge","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0025","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00345-020-03130-1","article-title":"Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer","volume":"38","author":"Krajewski","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0026","doi-asserted-by":"crossref","first-page":"e16223","DOI":"10.1097\/MD.0000000000016223","article-title":"The impact of age on intravesical instillation of Bacille Calmette-Guerin treatment in patients with high-grade T1 bladder cancer","volume":"98","author":"Calo","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urolonc.2025.02.004_bib0027","doi-asserted-by":"crossref","first-page":"21.e21","DOI":"10.1016\/j.urolonc.2023.09.010","article-title":"Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions","volume":"42","author":"Durant","year":"2024","journal-title":"Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T10:42:42Z","timestamp":1748428962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1078143925000304"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of age on BCG treatment response","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}